Market Place
Sourcing Support
Lilly signs $140M upfront partnership with Radionetics in radiopharma play
01 Jul 2024 //
FIERCE BIOTECH
Lilly Completes Acquisition of POINT Biopharma
27 Dec 2023 //
PR NEWSWIRE
POINT Biopharma shareholders get long-awaited radioligand therapy data
20 Dec 2023 //
PRESS RELEASE
Lantheus and POINT Biopharma Announce Positive Results from SPLASH Trial
18 Dec 2023 //
GLOBENEWSWIRE
Deadline for Point investors as data meets Lilly`s expectations
18 Dec 2023 //
FIERCE BIOTECH
Eli Lilly extends tender offer to buy Point Biopharma after low participation
17 Nov 2023 //
REUTERS
Lilly Announces the Receipt of NRC Consent in Connection with POINT Biopharma
14 Nov 2023 //
PR NEWSWIRE
POINT Biopharma Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Lilly enters radiopharmaceuticals with $1.4B Point Biopharma buy
04 Oct 2023 //
FIERCE BIOTECH
POINT Biopharma and Athebio Announce Partnership
18 Sep 2023 //
GLOBENEWSWIRE
POINT Biopharma Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
31 Jul 2023 //
GLOBENEWSWIRE
POINT Biopharma Expands Its Research with Next-Generation Isotopes
26 Jun 2023 //
GLOBENEWSWIRE
POINT Biopharma, AdvanCell Partner to Develop Lead-212-Labeled Radioligand
26 Jun 2023 //
CONTRACT PHARMA
Isotopia Molecular Imaging today announced the appointment of Todd Hockemeyer
20 Jun 2023 //
PR NEWSWIRE
POINT Biop Announces Appointment of Dr. Bridget Martell to Board of Directors
12 Jun 2023 //
GLOBENEWSWIRE
POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
07 Jun 2023 //
GLOBENEWSWIRE
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
25 May 2023 //
GLOBENEWSWIRE
POINT Biopharma Reports 1Q 2023 FYR Results and Provides Business Highlights
15 May 2023 //
GLOBENEWSWIRE
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting
15 May 2023 //
GLOBENEWSWIRE
Lantheus & POINT Biopharma Announce FDA Grants Fast Track Designation f
24 Apr 2023 //
GLOBENEWSWIRE
Eckert & Ziegler to Supply Point Biopharma with Actinium-225
04 Apr 2023 //
GLOBENEWSWIRE
POINT Reports Fourth Quarter and Full Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
POINT Biopharma Confirms Clinical Supply for the 177Lu-PNT2002 SPLASH Trial
07 Mar 2023 //
GLOBENEWSWIRE
POINT Biopharma to Participate in Upcoming Investor Conferences
02 Feb 2023 //
GLOBENEWSWIRE
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
12 Jan 2023 //
GLOBENEWSWIRE
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
20 Dec 2022 //
GLOBENEWSWIRE
POINT Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555
29 Nov 2022 //
GLOBENEWSWIRE
Lantheus pledges up to $2B for 2 of POINT`s radiopharmaceuticals
15 Nov 2022 //
FIERCEBIOTECH
POINT Biopharma Reports 3Q 2022 Financial Results & Strategic Collaboration
14 Nov 2022 //
GLOBENEWSWIRE
POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001
17 Oct 2022 //
GLOBENEWSWIRE
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares
16 Sep 2022 //
GLOBENEWSWIRE
POINT Biopharma Prices Public Offering of Common Stock
13 Sep 2022 //
GLOBENEWSWIRE
POINT Provides Updated Safety Data from PIII SPLASH Trial in mCRPC at ESMO 2022
09 Sep 2022 //
GLOBENEWSWIRE
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022
02 Sep 2022 //
FIRSTWORDPHARMA
POINT Biopharma to Publish Abstract at ESMO Congress 2022
18 Aug 2022 //
GLOBENEWSWIRE
POINT Biopharma Reports Second Quarter 2022 Financial Results
12 Aug 2022 //
GLOBENEWSWIRE
POINT Biopharma to Host Investor Education Event on PNT2002
08 Aug 2022 //
GLOBENEWSWIRE
POINT Biopharma to Participate in Upcoming Investor Conferences
06 Jul 2022 //
GLOBENEWSWIRE
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
21 Jun 2022 //
POINTBIOPHARMA
POINT Biopharma to Participate in Upcoming Investor Conferences
19 May 2022 //
GLOBENEWSWIRE
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
16 May 2022 //
GLOBENEWSWIRE
POINT Biopharma Reports First Quarter 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002
05 May 2022 //
GLOBENEWSWIRE
POINT Biopharma to Present Pan-Cancer FAP-Alpha Targeted Program at AACR
11 Apr 2022 //
GLOBENEWSWIRE
POINT Biopharma Reports Fiscal 2021 Financial Results
25 Mar 2022 //
GLOBENEWSWIRE
POINT Biopharma Confirms No Delays to SPLASH Trial
22 Mar 2022 //
GLOBENEWSWIRE
POINT Biopharma to Host Dosimetry Investor Education Event on March 29, 2022
15 Mar 2022 //
GLOBENEWSWIRE
POINT Biopharma Announces Abstract Publication of Dosimetry Data
25 Feb 2022 //
GLOBENEWSWIRE
POINT Provides Update on Manufacturing, Supply Chain and Late-Stage Programs
01 Feb 2022 //
GLOBENEWSWIRE
POINT Biopharma Licenses Innovative Lu-177 Production Technology
24 Nov 2021 //
GLOBENEWSWIRE
POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement
09 Nov 2021 //
GLOBENEWSWIRE
POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement
29 Oct 2021 //
GLOBENEWSWIRE
POINT Biopharma Releases New Data and Exercises Option
28 Sep 2021 //
GLOBENEWSWIRE
POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH
23 Sep 2021 //
GLOBENEWSWIRE
Convergent Therapeutics and Point Biopharma to Evaluate CONV 01-? + PNT2002
14 Sep 2021 //
PRNEWSWIRE
Point Biopharma soars 8% amid team up with Convergent
14 Sep 2021 //
SEEKINGALPHA
NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement
08 Sep 2021 //
BUSINESSWIRE
POINT Biopharma Reports Second Quarter 2021 Financial Results
13 Aug 2021 //
GLOBENEWS WIRE
POINT Biopharma Debuts as Publicly Traded Next-Gen Radiotherapeutics Company
01 Jul 2021 //
BIOSPACE
